Product Description
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
Mechanisms of Action: CTGF Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Fast Track - Muscular Dystrophies|Muscular Dystrophy, Duchenne *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: FibroGen
Company Location: SAN FRANCISCO CA 94158
Company CEO: Enrique Conterno
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Canada, Chile, China, France, Germany, Hong Kong, Israel, Italy, Korea, Russia, South Korea, Spain, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
- Clinical Outcomes Reported - FibroGen presented P3 Pancreatic Cancer results on 2024-07-30 for Pamrevlumab
- Clinical Outcomes Reported - FibroGen announced they will present P2 Pancreatic Cancer results in 3Q24 for Pamrevlumab
Highest Development Phases
Phase 3: Adenocarcinoma|Idiopathic Pulmonary Fibrosis|Muscular Dystrophy, Duchenne|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2051210169 |
jRCT2051210169 | P3 |
Recruiting |
Idiopathic Pulmonary Fibrosis |
2023-09-30 |
|||
NCT04229004 |
PanCAN_Precision Promise | P3 |
Completed |
Adenocarcinoma|Pancreatic Cancer |
2025-02-05 |
2025-04-08 |
||
2020-000699-39 |
2020-000699-39 | P3 |
Completed |
Muscular Dystrophy, Duchenne |
2023-12-14 |
32% |
2025-07-09 |
Treatments |
2023-000321-80 |
2023-000321-80 | P2 |
Completed |
Muscular Dystrophy, Duchenne |
2023-01-22 |
50% |
2025-07-09 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
2019-001925-28 |
2019-001925-28 | P3 |
Completed |
Pancreatic Cancer |
2024-06-11 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT03941093 |
LAPIS | P3 |
Completed |
Pancreatic Cancer |
2024-06-11 |
35% |
2024-11-27 |
Primary Endpoints |
2020-000697-22 |
2020-000697-22 | P3 |
Active, not recruiting |
Idiopathic Pulmonary Fibrosis |
2021-11-02 |
2022-03-13 |
Treatments |